ChangeBridge: Patent Apps - Pharma (A61K)

Cleansing composition with carnosine, magnesium, caffeine

The USPTO has published a new patent application (US20260083658A1) for a personal cleansing composition. The composition includes carnosine, magnesium salt, caffeine, and transdermal absorption enhancers, designed for use in products like shower gels and soaps.

Patent Application for Whitening Cosmetic Composition with Artemisinic Acid

The USPTO has published a patent application (US20260083657A1) for a whitening cosmetic composition containing artemisinic acid, nicotinamide, and/or glutathione. The application, filed by Yunnan Botanee Bio-Technology Group Co., Ltd., describes a formulation designed to inhibit melanin production and reduce skin irritation.

Patent Application for Hyaluronic Acid Production Stimulation

The USPTO has published a new patent application (US20260083656A1) filed by Alastin Skincare, Inc. The application details compositions and methods for stimulating intrinsic hyaluronic acid production to improve skin moisture and elasticity. This is a routine publication of a patent application.

Patent Application: Compositions with Sophorolipids and Lactic Acid

The USPTO has published a new patent application (US20260083655A1) filed by Evonik Operations GmbH. The application describes compositions containing sophorolipids and lactic acid for cleaning or skin moisturizing. This is a routine filing for a new patent application.

Patent Application: Tumor Targeting Methods and Reagents

The USPTO has published a patent application (US20260083867A1) detailing methods and reagents for tumor targeting in cancer treatment. The application, filed on November 21, 2025, describes a combination therapeutic approach using agents with different biodistributions to enhance efficacy and reduce toxicity.

USPTO Patent for Implantable Biodegradable Drug Delivery Devices

The USPTO has published a patent application (US20260083665A1) for implantable and biodegradable drug delivery devices. The invention aims to deliver active pharmaceutical ingredients directly to target tissue sites using layered biodegradable polymers.

USPTO Patent Application for PSMA Ligands

The USPTO has published a new patent application (US20260083865A1) filed by 3B Pharmaceuticals GMBH for prostate specific membrane antigen (PSMA) ligands. The application details a compound of Formula (I) and its use in treating cancer.

Patent Application for Contrast Agents in Diagnostic Imaging

The USPTO has published a patent application (US20260083864A1) for a new class of compounds intended for use as contrast agents in diagnostic imaging, including computed tomography (CT) and magnetic resonance imaging (MRI). The application details specific compound formulas, metal chelates, and preparation methods.

Patent Application: Treating Brain Diseases with rAAV Particles

The USPTO has published a new patent application (US20260083862A1) from the University of Iowa Research Foundation detailing methods for treating brain diseases using rAAV particles administered via the cisterna magna. The application was filed on May 19, 2025.

Patent Application for Genome Editing Compositions and Methods

The USPTO has published a new patent application (US20260083860A1) for genome editing compositions and methods. The application, filed on August 19, 2025, by inventors Oscar ALVAREZ, Ming-Yue LEE, and Blair B. MADISON, details methods and compositions for functional genetic modifications.